Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Myelin Water Fraction of Slowly Evolving Lesions is Associated With Disability in Multiple Sclerosis
Multiple Sclerosis
P10 - Poster Session 10 (8:00 AM-9:00 AM)
3-017

SELs in Multiple Sclerosis (MS) may represent areas of chronic inflammation and demyelination. It is not well understood whether SELs are associated with more severe disease and disability. We hypothesize that SELs may be a biomarker of greater focal and global tissue injury in the MS brain. Previous work using MRI has shown that SELs are characterized by decreased MWF and increased QT1. 

To investigate the relationship between Expanded Disability Status Scale (EDSS) and myelin water fraction (MWF)/quantitative T1 (QT1) of lesions in relapsing Multiple Sclerosis (RMS) participants with and without slowly growing lesions (SELs).

Forty-nine participants with RMS (31 females; median age: 39; median EDSS: 2) participating in a substudy of OPERA II (NCT01412333) had mcDESPOT MRI acquired at 3T. MWF and QT1 maps were obtained from the mcDESPOT images. SELs were derived from T1- and T2-weighted images. Non-SELs were defined as all pre-existing T2 lesions not identified as SELs. Correlation between EDSS and MWF/QT1 was measured by Spearman correlation.

Thirty-two out of 49 participants had at least one SEL (SEL+), and 17 had no SELs (SEL-). Median (range) EDSS for SEL+/SEL- participants was 2(0-4.5)/2(0-4). Mean (standard deviation) MWF for SEL+ SELs was 0.12(0.03), SEL+ non-SELs 0.13(0.02), and SEL- non-SELs 0.15(0.02); QT1 for SEL+ SELs was 1615(232)ms, SEL+ non-SELs 1530(163)ms, and SEL- non-SELs 1415(128)ms. For SEL+ SELs, EDSS correlated with MWF (r=-0.36, p=0.04) and QT1 (r=0.35, p=0.05), while for SEL+ non-SELs, trends toward correlation were found between EDSS and MWF (r=-0.31, p=0.089) and QT1 (r=0.32, p=0.076). For SEL- non-SELs, there was no significant correlation between EDSS and MWF or QT1 .

Greater tissue damage within SELs is associated with worse baseline disability. Tissue damage and demyelination in T2 lesions in participants with at least one SEL may have a stronger association with disability compared to participants who have no SELs.

Authors/Disclosures
Shannon Kolind, PhD, MSc, BSc (University of British Columbia)
PRESENTER
Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. The institution of Dr. Kolind has received research support from Sanofi Genzyme. The institution of Dr. Kolind has received research support from Roche. The institution of Dr. Kolind has received research support from Biogen.
Rebecca Zhuang Miss Zhuang has nothing to disclose.
Irene Vavasour, PhD (University of British Columbia) Dr. Vavasour has nothing to disclose.
Colm Elliott (NeuroRx Research) Colm Elliott has received personal compensation for serving as an employee of NeuroRx Research.
Douglas L. Arnold, MD, FAAN (Montreal Neurological Institute, McGill Univ) Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Celgene. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has stock in NeuroRx.
David Clayton David Clayton has received personal compensation for serving as an employee of Genentech/Roche. David Clayton has received stock or an ownership interest from Roche. An immediate family member of David Clayton has received publishing royalties from a publication relating to health care.
Stefano Magon No disclosure on file
Ulrike Bonati (Roche GLOBAL (PDN)) Ulrike Bonati has received personal compensation for serving as an employee of Hoffman-La Roche. An immediate family member of Ulrike Bonati has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for InnoHeart. The institution of an immediate family member of Ulrike Bonati has received research support from Astra Zeneca . The institution of an immediate family member of Ulrike Bonati has received research support from Bayer. The institution of an immediate family member of Ulrike Bonati has received research support from Stiftung zur Förderung der gastroenterologischen und allgemeinen klinischen Forschung sowie der medizinischen Bildauswertung. The institution of an immediate family member of Ulrike Bonati has received research support from Swiss Heart Foundation. The institution of an immediate family member of Ulrike Bonati has received research support from Swiss National Science Foundation.
Corrado Bernasconi Corrado Bernasconi has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Roche. Corrado Bernasconi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GeNeuro. Corrado Bernasconi has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Santhera.
Laura Gaetano Laura Gaetano has received personal compensation for serving as an employee of Roche. Laura Gaetano has received stock or an ownership interest from Roche.
Anthony Traboulsee, MD (University of British Columbia) Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EMD Serono. The institution of Dr. Traboulsee has received research support from Roche. The institution of Dr. Traboulsee has received research support from Genzyme.